From Liston Street Pulse:
Shares of GTx Inc. (GTXI), a biopharmaceutical company engaged in the development of selective androgen receptor modulators (SARMs), have plunged in trading today after the company reported results of its Phase 3 enobosarm clinical trials in patients with non-small lung cancer (NSCLC) receiving chemotherapy. The company said that the clinical trials failed to meet the […]
The post GTx Inc. Tumbles After Trial Results appeared first on Liston Street Pulse.
Created by Stock Researching | Dec 13, 2016
Created by Stock Researching | Dec 04, 2016
Created by Stock Researching | Dec 02, 2016
Created by Stock Researching | Nov 19, 2016
Created by Stock Researching | Nov 10, 2016
Created by Stock Researching | Oct 05, 2015